For innovators and investors, the path to developing a minimally invasive device for treating emphysema has been filled with both opportunity and obstacles. The market opportunity is vast. The global incidence of Chronic Obstructive Pulmonary Disease (COPD), which includes emphysema, is on the rise and will become the third leading cause of death by 2030. In the US, where nearly five million people are diagnosed with emphysema, the direct and indirect costs of COPD reached almost $50 billion in 2010, and the prevalence of patients with severe and very severe emphysema in key markets worldwide is estimated at more than 1.5 million, according to Uptake Medical Corp., a competitor in this space. (See Exhibit 1.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?